Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    9
ATC Name B/G Ingredients Dosage Form Price
L01EX08 LENVIMA B Lenvatinib - 4mg 4mg Capsule, hard L.L
R03DC03 LUKAST G Montelukast (sodium) - 4mg 4mg Tablet, chewable 783,460 L.L
R03DC03 LEUKOTRIS G Montelukast - 4mg 4mg Tablet 783,268 L.L
D01AE16 LOCERYL B Amorolfine - 125mg/2.5ml 5% Nail lacquer 1,076,418 L.L
C03CA01 LASIX B Furosemide - 500mg 500mg Tablet 1,454,038 L.L
J01MA02 LADININ G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 595,060 L.L
N03AX14 LEPITAM G Levetiracetam - 500mg 500mg Tablet 1,100,671 L.L
N03AX14 LEVETIRACETAM ARROW LAB G Levetiracetam - 500mg 500mg Tablet, film coated, breakable 2,441,762 L.L
N03AX14 LEVETIRACETAM BIOGARAN G Levetiracetam - 500mg 500mg Tablet, coated, scored 2,651,401 L.L
N03AX14 LEVIPHAR G Levetiracetam - 500mg 500mg Tablet, film coated 1,451,350 L.L
N03AX14 LEVIPRAM 500 G Levetiracetam - 500mg 500mg Tablet, film coated 1,663,805 L.L
J01MA12 LEFLUMAX G Levofloxacin (hemihydrate) - 500mg 500mg Tablet, film coated 752,552 L.L
J01MA12 LEVOFLOX G Levofloxacin - 500mg 500mg Tablet, coated, scored 602,041 L.L
J01MA12 LEVOKEY 500 G Levofloxacin (hemihydrate) - 500mg 500mg Tablet, film coated 141,103 L.L
J01MA12 LEVOMED G Levofloxacin (hemihydrate) - 500mg 500mg Tablet 849,820 L.L
J01MA12 LOXOF G Levofloxacin (hemihydrate) - 500mg 500mg Tablet, film coated 141,103 L.L
M03BA03 LUMIRELAX B Methocarbamol - 500mg 500mg Tablet 667,890 L.L
J01MA12 LEVOFLOXACIN COOPER G Levofloxacin (hemihydrate) - 500mg/100ml 500mg/100ml Injectable solution 959,504 L.L
J01MA12 LEVOFLOX-MEDIS 500 G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 1,834,345 L.L
J01MA12 LOXAMOX G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 747,176 L.L
N03AX14 LEVIPRAM IV G Levetiracetam - 500mg/100ml 500mg/100ml Injectable solution 1,869,733 L.L
J01GB06 LIKACIN G Amikacin (sulfate) - 500mg/2ml 500mg/2ml Injectable concentrated solution 349,399 L.L
C09CA01 LACINE 50 G Losartan potassium - 50mg 50mg Tablet, film coated 671,921 L.L
C09CA01 LOSANET G Losartan potassium - 50mg 50mg Tablet 395,474 L.L
C09CA01 LOSARTAN BIOGARAN G Losartan potassium - 50mg 50mg Tablet, coated, scored 439,436 L.L
N03AX09 LAMOTRIGINE ARROW LAB G Lamotrigine - 50mg 50mg Tablet, dispersible/ chewable 1,052,229 L.L
C09CA01 LOSARTAN-REMEDICA G Losartan potassium - 50mg 50mg Tablet, film coated 642,357 L.L
N03AX09 LAMOTRIGINE BIOGARAN G Lamotrigine - 50mg 50mg Tablet, dispersible 985,037 L.L
N03AX09 LAMOTRIGINE NORMON G Lamotrigine - 50mg 50mg Tablet, dispersible/ chewable 1,643,519 L.L
N03AX09 LAMICTAL B Lamotrigine - 50mg 50mg Tablet 1,753,895 L.L
    ...
    9
Sitemap
© Copyrights reserved to Ministry of Public Health 2025